Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B

• Main Authors: Zeuzem, S., Gane, E., Liaw, Y.-F., Lim, S.G., DiBisceglie, A., Buti, M., Chutaputti, A., Rasenack, J., Hou, J., O'Brien, C., Nguyen, T.T., Jia, J., Poynard, T., Belanger, B., Bao, W., Naoumov, N.V.
• Other Authors: MEDICINE
• Format: Article
• Published: 2016
• Subjects: Chronic hepatitis B; GLOBE trial; Lamivudine; Predictors; Telbivudine
• Online Access: http://scholarbank.nus.edu.sg/handle/10635/129754
• Institution: National University of Singapore

10.1016/j.jhep.2008.12.019